eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

Corporate Breaking News

Home : eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

Mar 19 2018	eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
NIEL, Belgium, March 19, 2018 /PRNewswire/ -- ECI-006 is safe and well tolerated eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose...


Source:https://www.prnewswire.com/news-releases/etherna-completes-enrolment-of-low-dose-cohort-for-phase-1b-study-of-trimix-mrna-based-cancer-specific-immunotherapy-eci-006-in-melanoma-677234353.html

Related News
» La alcaldesa de Seattle Durkan, Amazon, Starbucks, Zillow y otros se reúnen para discutir soluciones a la falta de techo como parte de la Bolsa de Recursos Comunitarios de United Way » DSM Announces Repurchase of Shares to Cover Share Based Compensation Plans and Stock Dividend